Can we decide the optimal initial treatment for male lower urinary tract symptoms patients with overactive bladder by the most bothersome symptom? A randomized, prospective, open-label study

Urologia Internationalis

Volumn 93, Issue 3, 2014, Pages 338-343

  Yun, Jong Hyun ^a   Kim, Jae Heon ^b   Kim, Jae Ho ^a   Lee, Sang Wook ^c   Yang, Hee Jo ^d   Doo, Seung Whan ^b   Yang, Won Jae ^b  

^a Soonchunhyang University College of Medicine   (South Korea)

^b Soonchunhyang University   (South Korea)

^c Bucheon Hospital   (South Korea)

^d Cheonan Hospital   (South Korea)

Author keywords

Outcome assessment; Prostatic hyperplasia; Prostatism

Indexed keywords

SOLIFENACIN; TAMSULOSIN; MUSCARINIC RECEPTOR BLOCKING AGENT; QUINUCLIDINE DERIVATIVE; SULFONAMIDE; TETRAHYDROISOQUINOLINE DERIVATIVE;

ADULT; ARTICLE; CONTROLLED STUDY; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MICTURITION; OVERACTIVE BLADDER; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; AGED; DECISION MAKING; LOWER URINARY TRACT SYMPTOMS; MIDDLE AGED; PROSTATE; SOUTH KOREA; SYMPTOM ASSESSMENT; URINARY BLADDER, OVERACTIVE;

AGED; DECISION MAKING; HUMANS; LOWER URINARY TRACT SYMPTOMS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PROSPECTIVE STUDIES; PROSTATE; QUALITY OF LIFE; QUINUCLIDINES; REPUBLIC OF KOREA; SULFONAMIDES; SYMPTOM ASSESSMENT; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URINATION;

EID: 84908566314     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000365335     Document Type: Article

References (27)

1. Chapple CR: Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: An overview for the practising clinician. BJU Int 2004; 94: 738-744.
2. Chapple CR, Roehrborn CG: A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: Focus on the bladder. Eur Urol 2006; 49: 651-658.
3. Chapple C, Herschorn S, Abrams P, Sun F, Brodsky M, Guan Z: Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alphablockers. Eur Urol 2009; 56: 534-541.
4. Kaplan SA, McCammon K, Fincher R, Fakhoury A, He W: Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. J Urol 2009; 182: 2825-2830.
5. Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z: Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: A randomized controlled trial. JAMA 2006; 296: 2319-2328.
6. Jepsen JV, Bruskewitz RC: Comprehensive patient evaluation for benign prostatic hyperplasia. Urology 1998; 51: 13-18.
7. Welch G, Weinger K, Barry MJ: Quality-oflife impact of lower urinary tract symptom severity: Results from the Health Professionals Follow-up Study. Urology 2002; 59: 245-250.
8. Lee YS, Lee HN, Han JY, Choo MS, Lee KS: Most bothersome symptom and symptom specific goal achievement in patients with benign prostatic obstruction: A prospective open label study. J Urol 2011; 185: 1003-1009.
9. Brubaker L, Khullar V, Piault E, Evans CJ, Bavendam T, Beach J, Yeh Y, Kopp ZS, Kelleher CJ, Trocio J: Goal attainment scaling in patients with lower urinary tract symptoms: Development and pilot testing of the Self-Assessment Goal Achievement (SAGA) questionnaire. Int Urogynecol J 2011; 22: 937-946.
10. Brubaker L, Piault EC, Tully SE, Evans CJ, Bavendam T, Beach J, Yeh Y, Kopp ZS, Khullar V, Kelleher CJ, Trocio J: Validation study of the Self-Assessment Goal Achievement (SAGA) questionnaire for lower urinary tract symptoms. Int J Clin Pract 2013; 67: 342-350.
11. Chang HS, Park CH, Kim DK, Park JK, Hong SJ, Chung BH, Lee JG, Kim CS, Lee KS, Kim JC: Assessment of patient-reported outcome of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and treated with tamsulosin HCl in Korea. Urology 2010; 75: 1156-1161.
12. Viktrup L, Hayes RP, Wang P, Shen W: Construct validation of patient global impression of severity (PGI-S) and improvement (PGI-I) questionnaires in the treatment of men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. BMC Urol 2012; 12: 30.
13. Yamaguchi O, Kakizaki H, Homma Y, Takeda M, Nishizawa O, Gotoh M, Yokoyama O, Seki N, Yoshida M: Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms - ASSIST, randomized controlled study. Urology 2011; 78: 126-133.
14. Lee SH, Byun SS, Lee SJ, Kim KH, Lee JY: Effects of initial combined tamsulosin and solifenacin therapy for overactive bladder and bladder outlet obstruction secondary to benign prostatic hyperplasia: A prospective, randomized, multicenter study. Int Urol Nephrol 2014; 46: 523-529.
15. Apostolidis A, Kirana PS, Chiu G, Link C, Tsiouprou M, Hatzichristou D: Gender and age differences in the perception of bother and health care seeking for lower urinary tract symptoms: Results from the hospitalised and outpatients' profile and expectations study. Eur Urol 2009; 56: 937-947.
16. Roe B, Doll H, Wilson K: Help seeking behaviour and health and social services utilisation by people suffering from urinary incontinence. Int J Nurs Stud 1999; 36: 245-253.
17. Teunissen D, van Weel C, Lagro-Janssen T: Urinary incontinence in older people living in the community: Examining help-seeking behaviour. Br J Gen Pract 2005; 55: 776-782.
18. Elinoff V, Bavendam T, Glasser DB, Carlsson M, Eyland N, Roberts R: Symptom-specific efficacy of tolterodine extended release in patients with overactive bladder: The IMPACT trial. Int J Clin Pract 2006; 60: 745-751.
19. Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, N'Dow J, Nordling J, de la Rosette JJ: EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 2013; 64: 118-140.
20. Lee SW, Doo SW, Yang WJ, Song YS: Importance of relieving the most bothersome symptom for improving quality of life in male patients with lower urinary tract symptoms. Urology 2012; 80: 684-687.
21. Roehrborn CG, Kaplan SA, Kraus SR, Wang JT, Bavendam T, Guan Z: Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB. Urology 2008; 72: 1061-1067; discussion 1067.
22. Pleil AM, Coyne KS, Reese PR, Jumadilova Z, Rovner ES, Kelleher CJ: The validation of patient- rated global assessments of treatment benefit, satisfaction, and willingness to continue - The BSW. Value Health 2005; 8(suppl 1): S25-S34.
23. Shah S, Nitti VW: Defining efficacy in the treatment of overactive bladder syndrome. Rev Urol 2009; 11: 196-202.
24. Burgio KL, Locher JL, Goode PS, Hardin JM, McDowell BJ, Dombrowski M, Candib D: Behavioral vs drug treatment for urge urinary incontinence in older women: A randomized controlled trial. JAMA 1998; 280: 1995-2000.
25. Takeda M, Nishizawa O, Gotoh M, Yoshida M, Takahashi S, Masumori N: Clinical efficacy and safety of imidafenacin as add-on treatment for persistent overactive bladder symptoms despite a-blocker treatment in patients with BPH: The ADDITION study. Urology 2013; 82: 887-893.
26. Krhut J, Gartner M, Petzel M, Sykora R, Nemec D, Tvrdik J, Skoupa J: Persistence with first line anticholinergic medication in treatment- naive overactive bladder patients. Scand J Urol 2014; 48: 79-83.
27. Chancellor MB, Migliaccio-Walle K, Bramley TJ, Chaudhari SL, Corbell C, Globe D: Longterm patterns of use and treatment failure with anticholinergic agents for overactive bladder. Clin Ther 2013; 35: 1744-1751.